The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Rationale and efficacy of fecal transplantation for ICI colitis
Yinghong Wang, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, explains that fecal transplantation restores gut microbiota, reducing inflammation and alleviating immune checkpoint inhibitors (ICI) colitis. This treatment offers a natural and effective alternative to immunosuppressants, with studies showing significant microbiome changes and potential as a future standard of care. This interview took place during the 2024 ASCO Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MIMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – BioNTech; Ilya Pharma; IOTA Pharmaceuticals; Janssen; Kanvas Biosciences; Mallinckrodt; Sorriso Pharmaceuticals
Patents, Royalties, Other Intellectual Property – Springer
